Exchange: NYSE·Updated 07:59 PM EDT
News
all
press releases
GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)
Key PointsAmgen is developing a highly differentiated GLP-1 product...
Nasdaq News: Markets
More News
Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger
Key PointsIts drug, Foundayo, will compete in Britain against Novo Nordisk's Wegovy...
Nasdaq News: Markets
Should Investors Buy WST as HVP Growth Meets a Premium Valuation?
WST's faster HVP growth, wider margins and stronger earnings outlook support the bull case, but its premium valuation leaves less room for error.
Zacks
WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story
West Pharmaceutical's Q2 beat, faster HVP growth and wider margins drove a higher 2026 outlook, strengthening its earnings case.
Zacks
Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?
NVO's GLP-1 pills offer fresh momentum, but Eli Lilly's fast-growing injectable and oral therapies threaten to widen the competitive gap.
Zacks
LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?
Lilly's Foundayo records $98M in Q2 sales, while rising prescriptions, broader access and global expansion set the stage for H2 growth
Zacks
Novo Nordisk CEO Mike Doustdar sits down with Jim Cramer
Novo Nordisk CEO Mike Doustdar sits down with Jim Cramer...
CNBC Television-YouTube
Novo Nordisk CEO defends lawsuit against Eli Lilly: 'Competition has to be fair'
Novo Nordisk CEO defended the company's decision to sue rival Eli Lilly over its weight-loss drug advertising...
CNBC: Mad Money with Jim Cramer
Novo Nordisk CEO sees 'long runway' for weight-loss drugs as obesity grips America
The boom in weight-loss drugs may have transformed the obesity market, but Novo Nordisk's CEO says the industry is still only scratching the surface with tens of millions of Americans potentially eligible for treatment.Novo Nordisk President and CEO Mike Doustdar joined FOX Business' Cheryl Casone...
FOXBusiness.com - Business/Financial
Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?
NVO faces near-term pressure from flat Wegovy sales, pricing challenges and pipeline setbacks, but its broad cardiometabolic pipeline offers long-term potential.
Zacks

Advertisement|Remove ads.